Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
April 27, 2018
Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed/Refractory AML Patient
MONT-SAINT-GUIBERT, Belgium, April 27, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (CYAD), a clinical-stage biopharmaceutical company focused on the development of CART-cell therapies, ...
April 27, 2018
Moberg Pharma Completes Divestment of Balmex® for $4.25 million
STOCKHOLM, April 27, 2018 /PRNewswire/ --  Moberg Pharma AB (OMX:MOB) has completed the divestment of the Balmex® brand to Randob Labs for a total consideration ...
April 27, 2018
Zogenix Announces Initial Quality of Life and Cognitive Function Data From Phase 3 Trial of ZX008 in Dravet Syndrome
EMERYVILLE, Calif., April 27, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) ...
April 27, 2018
CorMedix Revises Timeline and Announces Changes to Lock-It-100 Study Management
BERKELEY HEIGHTS, NJ / ACCESSWIRE / April 27, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products ...
April 27, 2018
Spring Bank Pharmaceuticals Provides Corporate Update and Reports First Quarter Financial and Operational Results
HOPKINTON, Mass., April 27, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
April 27, 2018
HTG Molecular Diagnostics to Announce First Quarter Financial Results and Host Conference Call on Thursday, May 10
TUCSON, Ariz., April 27, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today ...
April 26, 2018
Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome
Copenhagen, Denmark, April 26, 2018 - Zealand Pharma (Zealand) today announced receipt of the End-of-Phase 2 meeting minutes from the U.S. Food and Drug Administration ...
April 26, 2018
BioTime to Announce First Quarter 2018 Results on May 10, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will release first quarter 2018 financial ...
April 26, 2018
Vermillion Announces Recognition by and Publication in Two Top Physician Educational Resources
AUSTIN, Texas, April 26, 2018 (GLOBE NEWSWIRE) -- ASPiRA LABs, a Vermillion company (VRML), today announced that two top physician educational resources, UpToDate and the ...
April 26, 2018
Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
ROCKVILLE, Md., April 26, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical-stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of ...
April 26, 2018
Krystal Biotech Announces FDA Clearance of IND on KB103 to Begin Enrolling Patients for the Treatment of Dystrophic Epidermolysis Bullosa
PITTSBURGH, April 26, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., ("Krystal") (KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare dermatological ...
April 26, 2018
Achaogen Wins CARB-X Funding Award to Advance Development of Novel Aminoglycoside to Fight Highly-Resistant Infections
SOUTH SAN FRANCISCO, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative ...
April 26, 2018
PolarityTE Leadership to Participate in the Symposium on Advanced Wound Care
SALT LAKE CITY, April 26, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (COOL) today announced attendance and participation in the Symposium on Advanced Wound Care Spring ...
April 26, 2018
Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018
WALTHAM, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
April 26, 2018
Transgene: €35.6 Million in Cash and Cash Equivalents as of March 31, 2018
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (TNG.PA) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases, today announces its ...
April 26, 2018
AIT Therapeutics Receives Patent Allowance for Delivery of Inhaled Nitric Oxide at Concentrations of at Least 160ppm for Treatment of Bronchiolitis in Infants
NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) --  AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide ...
April 25, 2018
Conatus Pharmaceuticals to Report First Quarter 2018 Financial Results
SAN DIEGO, April 25, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (CNAT) today announced that it will report financial results for the first quarter ended ...
April 25, 2018
ARMO BioSciences Announces Poster Presentations of Pegilodecakin (AM0010) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
REDWOOD CITY, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- ARMO BioSciences, Inc. (ARMO), a late-stage immuno-oncology company, today announced three abstracts on pegilodecakin (AM0010), a ...
April 25, 2018
FDA Determines that Afrezza REMS Communication Plan Has Met Goals and REMS No Longer Necessary
WESTLAKE VILLAGE, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD), focused on the development and commercialization of inhaled therapeutic products for patients with ...
April 25, 2018
Aptose Announces Appointment of Caroline M. Loewy to Board of Directors
SAN DIEGO and TORONTO, April 25, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (APTO) (APS.TO), a clinical-stage company developing highly differentiated therapeutics targeting the underlying ...
Page 68 of 138